TEVA-Betahistine Tablets: Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-betahistine.
Brand(s)
Last updated
Summary
Product
TEVA-Betahistine Tablets
Issue
Health products - Product safety
What to do
Consult your health care professional if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| TEVA-Betahistine Tablets | TEVA-Betahistine Tablets 8mg | DIN 02280183 | Tablet | BETAHISTINE HYDROCHLORIDE 8mg | 100043755 100047041 100054115 100057407 |
| TEVA-Betahistine Tablets | TEVA-Betahistine Tablets 16mg | DIN 02280191 | Tablet | BETAHISTINE HYDROCHLORIDE 16mg | 100039202 100039975 100040342 100047037 100047038 100048555 100050930 100052559 100057107 100057408 100058036 100062444 100038357 100047367 |
| TEVA-Betahistine Tablets | TEVA-Betahistine Tablets 24mg | DIN 02280205 | Tablet | BETAHISTINE HYDROCHLORIDE 24mg | 100038340 100043738 100049891 100052857 100056000 100039609 100039610 100039611 100044222 100049365 100058037 |
Issue
Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-betahistine.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers, Pharmacy
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Teva Canada Limited.
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type I
Identification number
RA-76642
Get notified
Receive emails about new and updated recall and safety alerts.